Antigestagene

J F van Uem, van Uem JF, G. D. Hodgen, Hodgen GD
Geburtshilfe und Frauenheilkunde · 1988 · vol. 48(12) , pp. 829–834 · doi:10.1055/s-2008-1026636 · PMID:3069562 · W4253692283
review OA: closed CC0
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This paper discusses novel 19-norprogestin derivatives of the RU 486 type, exploring their potential therapeutic applications in fertility control, cancer, endometriosis, and labor induction.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-09 · read from full text ⓘ

This short review describes recently developed potent 19-norprogestin derivatives of the RU 486 type that act at the receptor level and are presented as a major breakthrough in steroid endocrinology. It notes that clinical studies suggest potential use for fertility control and outlines broader biochemical, pharmacological, and clinical aspects of antiprogestins. The paper also discusses their expected roles in therapeutic management of certain endometrial and breast cancers, endometriosis, and in inducing labor at term, without detailing study results or specific data. This paper is centrally about endometriosis — it explicitly discusses antiprogestins (RU 486-type 19-norprogestins) in relation to endometriosis therapy, alongside other indications.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Recently potent 19-norprogestin derivatives of the RU 486-type were developed. Acting at the receptor level, these steroids are considered a major breakthrough in steroid endocrinology. Clinical studies indicate their potential use in fertility control. Besides biochemical, pharmacological and clinical aspects of the antiprogestins, the ultimate role in the therapeutic management of certain endometrial and breast cancers, endometriosis as well as induction of labour at term are discussed.
Full text 1,468 characters · extracted from oa-doi-fallback · click to expand
Subscribe to RSS DOI: 10.1055/s-2008-1026636 © Georg Thieme Verlag Stuttgart · New York Antigestagene Antigestagens * The Jones Institute for Reproductive Medicine Medical College of Hampton Roads Eastern Virgina Medical School, 855 West Brambleton Avenue Norfolk, Va 23510, USAPublication History Publication Date: 16 June 2008 (online) Zusammenfassung Potente 19-Norprogestinderivate des Typs RU 486 sind kürzlich entwickelt worden, die auf der Rezeptorenebene angreifen und als bedeutsamer Durchbruch auf dem Gebiet der Steroid-Endokrinologie angesehen werden. Klinische Studien haben ihre potentielle Anwendung auf dem Gebiet der Empfängnisverhütung als zukunftsträchtig ausgewiesen. Neben den biochemischen, pharmakologischen und klinischen Aspekten der Antiprogestine wird auch ihre zu erwartende Bedeutung in der Behandlung bestimmter endometrischer und Mammakarzinome und der Endometriose sowie bei der Weheneinleitung bei termingerechter Geburt diskutiert. Abstract Recently potent 19-norprogestin derivatives of the RU 486-type were developed. Acting at the receptor level, these steroids are considered a major breakthrough in steroid endocrinology. Clinical studies indicate their potential use in fertility control. Besides biochemical, pharmacological and clinical aspects of the antiprogestins, the ultimate role in the therapeutic management of certain endometrial and breast cancers, endometriosis as well as induction of labour at term are discussed.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Contraceptives, Oral, Synthetic Estrenes Progestins Animals Contraceptives, Oral, Synthetic Estrenes Female Humans Mifepristone Pregnancy Progestins Structure-Activity Relationship

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-03T06:10:56.557307+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:20.810540+00:00
License: CC0 · commercial use OK